Press

Registry data is helping to bridge the gap between the FTD and ALS research communities and to accelerate recruitment for future clinical trials.

Registry data reveal which FTD subtypes and genes have the highest representation of research-ready participants, helping scientists design stronger, more focused studies.

Alector has announced topline results from its Phase 3 INFRONT-3 trial of latozinemab for FTD-GRN.

Life with FTD is about so much more than medical symptoms. To better understand the impact of FTD disorders, our September Quick Question asked …

Progress is possible. See how Registry data can unlock breakthroughs in FTD research just as new treatments are showing progress in other neurological disorders.

Only a fraction of people with FTD and their relatives pursue genetic testing. This World FTD Awareness Week, discover how genetic counseling can guide the way.

Caring for a loved one with FTD can make research participation feel impossible. Learn more about the barriers caregivers face and how researchers can make studies more accessible.

Every survey response in the Registry Research Study helps turn lived experience into research data that drives discovery.

World FTD Awareness Week is September 21-27, 2025.

528 participants responded to the FTD Disorders Registry’s August Quick Question on health insurance coverage.